U.S. markets open in 1 hour 51 minutes

Sumitomo Chemical Company, Limited (SOMMY)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
20.01-0.15 (-0.72%)
At close: 03:45PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close20.16
Bid0.00 x 0
Ask0.00 x 0
Day's Range19.93 - 20.07
52 Week Range17.63 - 27.99
Avg. Volume45,172
Market Cap6.682B
Beta (5Y Monthly)0.98
PE Ratio (TTM)5.41
EPS (TTM)3.70
Earnings DateN/A
Forward Dividend & Yield0.98 (4.91%)
Ex-Dividend DateMar 29, 2022
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for SOMMY

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    Analyst Report: MERCK Kommanditgesellschaft auf AktienMerck KGaA operates in three main segments: life sciences, performance materials, and healthcare. The life sciences segment (46% of 2021 sales) provides laboratory consumables and instruments to researchers in academia and applied fields, including the biopharmaceutical industry. In the healthcare segment (36%), Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In its electronics segment (18%), the company offers specialty materials to manufacture a variety of products, such as semiconductors, flat-screen televisions, automobiles, and cosmetics. In 1995, the E. Merck KG family publicly sold part of the company, resulting in the current 30% public ownership of the firm.
    Fair Value
    Economic Moat
    4 days agoMorningstar
View more
  • PR Newswire

    Ginkgo Bioworks Announces Latest Collaboration for Beauty and Personal Care Industry with Sumitomo Chemical

    Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced the launch of a new cell programming project as part of a broader collaboration with Sumitomo Chemical Co., Ltd (TSE:4005), one of Japan's leading chemical companies. Through this partnership, Sumitomo Chemical will leverage Ginkgo's extensive codebase and expertise in organism engineering to produce molecules in a sustainable fashion that are used in products across a broad range of industries. Th